ERBB2 and breast carcinoma: The tetra-specific multivalent methotrexate-loaded nanobody PEGylated liposomes appeared to have more binding avidity and cytotoxicity in HER2-overexpressing breast cancer cells (BT-474 and SKBR-3 cell lines) compared to the top-acting monoclonal nanobody vesicles.